Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

BACKGROUND Coding variants in the apolipoprotein L1 gene (APOL1) are strongly associated with non-diabetic nephropathy in African Americans. ApoL1 proteins associate with high-density lipoprotein (HDL) particles in the circulation. Plasma HDL particle subclass concentrations were compared in 73 African Americans based on APOL1 genotypes to detect differences potentially contributing to renal disease. METHODS HDL subclass concentrations were measured using nuclear magnetic resonance spectroscopy in African American first-degree relatives of patients with non-diabetic end-stage renal disease. Participants had estimated glomerular filtration rates (GFRs) > 80 mL/min and lacked albuminuria. Additive effects of the number of APOL1 risk variants on natural logarithm-transformed HDL subclass concentrations were computed. RESULTS Participants were 58.9% female with mean ± SD age 47.2 ± 13.3 years and GFR 92.4 ± 18.8 mL/min. The numbers with 2, 1 and 0 APOL1 nephropathy risk variants, respectively, were 36, 17 and 20. Mean ± SD medium-sized HDL concentrations were significantly lower for each additional APOL1 risk variant (2 versus 1 versus 0 risk variants: 9.0 ± 5.6 versus 10.1 ± 5.5 versus 13.1 ± 8.2 μmol/L, respectively; P = 0.0222 unadjusted; P = 0.0162 triglyceride- and ancestry adjusted). CONCLUSIONS Lower medium-sized HDL subclass concentrations are present in African Americans based on increasing numbers of APOL1 nephropathy risk variants. Potential mechanistic roles of altered medium HDL concentrations on APOL1-associated renal microvascular diseases should be evaluated.

[1]  C. Langefeld,et al.  Response to Mechanism of Action of APOL1 in Renal Allograft Survival (and Native CKD) Remains Unclear , 2011 .

[2]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[4]  B. Freedman,et al.  Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[5]  Keith C. Norris,et al.  Intensive blood-pressure control in hypertensive chronic kidney disease. , 2010, The New England journal of medicine.

[6]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[7]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[8]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[9]  B. Freedman,et al.  The spectrum of MYH9-associated nephropathy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[10]  B. Freedman,et al.  Essential hypertension and risk of nephropathy: a reappraisal , 2010, Current opinion in nephrology and hypertension.

[11]  C. Langefeld,et al.  Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  Amanda L. Brown,et al.  Apolipoprotein M expression increases the size of nascent preβ HDL formed by ATP binding cassette transporter A1 , 2010, Journal of Lipid Research.

[13]  C. Winkler,et al.  Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15 , 2010, Human molecular genetics.

[14]  C. Winkler,et al.  Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Yongmei Liu,et al.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. , 2009, Kidney international.

[16]  M. Leppert,et al.  Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene (MYH9) Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study , 2009, American Journal of Nephrology.

[17]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[18]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[19]  Donald W. Bowden,et al.  Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease , 2008, Human Genetics.

[20]  Keith C. Norris,et al.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. , 2008, Archives of internal medicine.

[21]  L. Kuller,et al.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.

[22]  B. Dahlbäck,et al.  An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma Published, JLR Papers in Press, May 25, 2007. , 2007, Journal of Lipid Research.

[23]  W. Cromwell,et al.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.

[24]  M. Salvadori,et al.  FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  M. Hayden,et al.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.

[26]  Philip F Halloran,et al.  Immunosuppressive drugs for kidney transplantation. , 2004, The New England journal of medicine.

[27]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  R. Ferguson FTY720 immunomodulation: optimism for improved transplant regimens. , 2004, Transplantation proceedings.

[29]  T. Orchard,et al.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.

[30]  C. Marcantoni,et al.  Hypertensive nephrosclerosis in African Americans versus Caucasians. , 2002, Kidney international.

[31]  M. Jauhiainen,et al.  The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* , 2001, The Journal of Biological Chemistry.

[32]  P. Barter,et al.  Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.

[33]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[34]  P. Duchateau,et al.  Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas , 1997, The Journal of Biological Chemistry.

[35]  B. Freedman,et al.  The link between hypertension and nephrosclerosis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  L. Kuller,et al.  Lipoprotein subclass and particle size differences in Afro-Caribbeans, African Americans, and white Americans: associations with hepatic lipase gene variation. , 2006, Metabolism: clinical and experimental.

[37]  D. Freedman,et al.  Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. , 2002, Atherosclerosis.

[38]  J. Breyer,et al.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.

[39]  B. Freedman,et al.  Renal biopsy findings in presumed hypertensive nephrosclerosis. , 1994, American journal of nephrology.